Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Kimberly Clark Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Kimberly Clark Corp trades at $112.58 (market cap $37.31B). The key difference: Alnylam Pharmaceuticals, Inc. and Kimberly Clark Corp are close in size by market cap, and Kimberly Clark Corp pays a 4.55% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | KMB | |
|---|---|---|
Market Cap | $39.89B | $37.31B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $136.77 |
52-Week Low | $278.09 | $93.05 |
Enterprise Value | $38.15B | $43.86B |
Dividend Yield | — | 4.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Kimberly-Clark (KMB) trades at $112.41, up 2.26% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company maintains strong profitability with a 12.8% net income margin and a high ROE of 146.29%, though revenue declined to $16.45B in 2025. Recent news highlights its dividend reliability and upcoming Q2 2026 results announcement on August 4, 2026.
KMB offers a stable dividend yield and defensive appeal, but faces headwinds from revenue pressure and high valuation multiples. Analyst consensus is mixed with a $109 price target below the current price, suggesting cautious optimism. Key risks include consumer sentiment impacts and input cost inflation, requiring monitoring of margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
